Wall Street Interest In Biotech IPOs May Be Piqued By NDA Approvals
This article was originally published in The Pink Sheet Daily
Biotechs looking to go public could benefit from momentum from positive FDA reviews, Ernst & Young partner predicts.
You may also be interested in...
Number of biotech IPOs declined to 17 in 2005 as more firms seek to partner with “big pharma,” according to BIO Venture Forum East panelists.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.